Advanced

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

Mustjoki, S. ; Richter, Johan LU ; Barbany, G. ; Ehrencrona, Hans LU ; Fioretos, Thoas LU ; Gedde-Dahl, T. ; Gjertsen, B. T. ; Hovland, R. ; Hernesniemi, S. and Josefsen, D. , et al. (2013) In Leukemia 27(7). p.1520-1526
Abstract
Chronic myeloid leukemia (CML) stem cells appear resistant to tyrosine kinase inhibitors (TKIs) in vitro, but their impact and drug sensitivity in vivo has not been systematically assessed. We prospectively analyzed the proportion of Philadelphia chromosome-positive leukemic stem cells (LSCs, Ph+CD34+CD38=) and progenitor cells (LPCs, Ph+CD34+CD38+) from 46 newly diagnosed CML patients both at the diagnosis and during imatinib or dasatinib therapy (ClinicalTrials.gov NCT00852566). At diagnosis, the proportion of LSCs varied markedly (1-100%) between individual patients with a significantly lower median value as compared with LPCs (79% vs 96%, respectively, P = 0.0001). The LSC burden correlated with leukocyte count, spleen size, hemoglobin... (More)
Chronic myeloid leukemia (CML) stem cells appear resistant to tyrosine kinase inhibitors (TKIs) in vitro, but their impact and drug sensitivity in vivo has not been systematically assessed. We prospectively analyzed the proportion of Philadelphia chromosome-positive leukemic stem cells (LSCs, Ph+CD34+CD38=) and progenitor cells (LPCs, Ph+CD34+CD38+) from 46 newly diagnosed CML patients both at the diagnosis and during imatinib or dasatinib therapy (ClinicalTrials.gov NCT00852566). At diagnosis, the proportion of LSCs varied markedly (1-100%) between individual patients with a significantly lower median value as compared with LPCs (79% vs 96%, respectively, P = 0.0001). The LSC burden correlated with leukocyte count, spleen size, hemoglobin and blast percentage. A low initial LSC percentage was associated with less therapy-related hematological toxicity and superior cytogenetic and molecular responses. After initiation of TKI therapy, the LPCs and LSCs rapidly decreased in both therapy groups, but at 3 months time point the median LPC level was significantly lower in dasatinib group compared with imatinib patients (0.05% vs 0.68%, P = 0.032). These data detail for the first time the prognostic significance of the LSC burden at diagnosis and show that in contrast to in vitro data, TKI therapy rapidly eradicates the majority of LSCs in patients. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
CML, leukemia stem cell, tyrosine kinase inhibitor, progenitor
in
Leukemia
volume
27
issue
7
pages
1520 - 1526
publisher
Nature Publishing Group
external identifiers
  • wos:000321614000010
  • scopus:84880267713
ISSN
1476-5551
DOI
10.1038/leu.2013.19
language
English
LU publication?
yes
id
2e50fd0b-e81b-4cf1-bc39-6d9a0c41214b (old id 3974058)
date added to LUP
2016-04-01 14:32:10
date last changed
2019-10-23 03:27:35
@article{2e50fd0b-e81b-4cf1-bc39-6d9a0c41214b,
  abstract     = {Chronic myeloid leukemia (CML) stem cells appear resistant to tyrosine kinase inhibitors (TKIs) in vitro, but their impact and drug sensitivity in vivo has not been systematically assessed. We prospectively analyzed the proportion of Philadelphia chromosome-positive leukemic stem cells (LSCs, Ph+CD34+CD38=) and progenitor cells (LPCs, Ph+CD34+CD38+) from 46 newly diagnosed CML patients both at the diagnosis and during imatinib or dasatinib therapy (ClinicalTrials.gov NCT00852566). At diagnosis, the proportion of LSCs varied markedly (1-100%) between individual patients with a significantly lower median value as compared with LPCs (79% vs 96%, respectively, P = 0.0001). The LSC burden correlated with leukocyte count, spleen size, hemoglobin and blast percentage. A low initial LSC percentage was associated with less therapy-related hematological toxicity and superior cytogenetic and molecular responses. After initiation of TKI therapy, the LPCs and LSCs rapidly decreased in both therapy groups, but at 3 months time point the median LPC level was significantly lower in dasatinib group compared with imatinib patients (0.05% vs 0.68%, P = 0.032). These data detail for the first time the prognostic significance of the LSC burden at diagnosis and show that in contrast to in vitro data, TKI therapy rapidly eradicates the majority of LSCs in patients.},
  author       = {Mustjoki, S. and Richter, Johan and Barbany, G. and Ehrencrona, Hans and Fioretos, Thoas and Gedde-Dahl, T. and Gjertsen, B. T. and Hovland, R. and Hernesniemi, S. and Josefsen, D. and Koskenvesa, P. and Dybedal, I. and Markevarn, B. and Olofsson, Tobias and Olsson-Stromberg, U. and Rapakko, K. and Thunberg, S. and Stenke, L. and Simonsson, B. and Porkka, K. and Hjorth-Hansen, H.},
  issn         = {1476-5551},
  language     = {eng},
  number       = {7},
  pages        = {1520--1526},
  publisher    = {Nature Publishing Group},
  series       = {Leukemia},
  title        = {Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients},
  url          = {http://dx.doi.org/10.1038/leu.2013.19},
  doi          = {10.1038/leu.2013.19},
  volume       = {27},
  year         = {2013},
}